Jacob Plieth — So: $CTMX efficacy falls from 28% (n=18) to 20% (n=56) across all 3 doses.
Efficacy for 2 highest doses falls from 31% (n=13) to 26% (n=39).↗
Mar 16
Jacob Plieth — My $CTMX expectations, from earlier this month↗
Mar 16
Adam Feuerstein ✡️ — $CTMX colon cancer ADC study update
https://t.co/QGbBpyJ00E↗
Mar 4
Jacob Plieth — $CTMX, +660% in 12 months, approaches its masked ADC catalyst. Via @ApexOnco -> https://t.co/oQI1iQiV4N ( $JANX -58% in the same timeframe)↗
December 2025 · 1 mention
Dec 3
Jacob Plieth — $JANX ended -53%, $CTMX -11%. Here's yesterday's take from @ByMadeleineA at @ApexOnco https://t.co/5cQ4Xw32YM↗
November 2025 · 1 mention
Nov 17
Jacob Plieth — $JNJ just acquired Halda for $3.05bn. Earlier story from @BatirtzeAreitio -> https://t.co/7nxuN3Oykj $JANX $CTMX↗
August 2025 · 2 mentions
Aug 13
Jacob Plieth — @NotthatkindofDr Oh, yes I see now. Thx, just catching up with this $CTMX https://t.co/BzFJplpmRX↗
Aug 13
Jacob Plieth — So all good still for $CTMX varsetatug masetecan (CX-2051)? Additional ph1 data by Q1 2026 is in line with January disclosure. What "recent social media posts" are they referring t…↗
July 2025 · 1 mention
Jul 25
Jacob Plieth — $JANX resurrects a TROP2 asset, and continues tinkering with CD28. Meanwhile, JANX007 & JANX008 data are a waiting game. Via @ApexOnco -> https://t.co/kqO2x7AYOv $CTMX↗